One Benefit We Don't See From RA Biologics One might have hoped that these agents would help patients stay on the job May 02, 2022
Biologics for JIA? Not So Fast, Say Insurers Nearly all required prior authorization in a small study, and requests often rejected at first Apr 24, 2022
Is Alzheimer's Risk Lower With TNF Inhibitors? For arthritis patients with cardiovascular disease, the answer may be yes Apr 08, 2022
'It's an Alien Knee in There': Mixed Feelings After Joint Replacement Study highlights common, but rarely discussed, problem Mar 28, 2022
Reassurance on Steroid Shots for Knee OA Study counters fears that injections worsen underlying pathology Mar 17, 2022
Ankylosing Spondylitis: Another Step Toward Individualized Therapy Study IDs factors predicting response to TNF inhibitors Mar 15, 2022
Hopes Dashed for Novel Osteoarthritis Treatment Noninvasive therapy looked like a sure winner until trial results came in Mar 08, 2022
Dyspnea in Woman With RA Reveals a Diaphragmatic Lipoma MRI can help differentiate these benign soft-tissue masses from more aggressive liposarcomas Feb 22, 2022
Two Years On, Tremfya Still Shines in Psoriatic Arthritis Efficacy increases in long-term extension data Feb 10, 2022
Mystery: Why Would Hand OA Be Less Severe in Black People? Data contrast with previous findings for hip and knee osteoarthritis Feb 04, 2022
Trial Data Confirm Heightened Risks With JAK Inhibitor May help patients and clinicians better weigh benefit against adverse effects Jan 26, 2022
Muddled Picture for Antidepressant as Osteoarthritis Pain Reliever Trial in primary care setting fails to confirm benefit seen in specialty clinics Jan 06, 2022
Success for Upadacitinib in PsA, Despite Concerns JAK inhibitor nabs new indication after FDA called for boxed warnings on the class Dec 28, 2021
Hydroxychloroquine Linked to Less Heart Risk in RA, Lupus Current use of the antimalarial especially was particularly associated with less thrombosis Dec 28, 2021
Another Trial, Another PRP Flop in Osteoarthritis Fails to outperform saline in randomized trial Nov 23, 2021
Another Study Confirms Gout Benefit With SGLT2 Inhibitors Gout risk reduction was significantly better than with DPP-4 inhibitors Nov 19, 2021
Biologic Disappoints for Arthritis Achilles' Inflammation But phase III trial did find some patient-oriented benefits Nov 11, 2021
Vitamin D and Disease Prevention: Worth Another Look? Incidence of autoimmune disease decreased by 25-30% with dietary supplements Nov 08, 2021
Guselkumab Response Durable in Psoriatic Arthritis Skin and joint improvements persisted through 2 years of follow-up Nov 08, 2021
Early Biologics Better in Juvenile Idiopathic Arthritis After 2 years, more patients on combo biologic/DMARD regimen had inactive disease Nov 08, 2021
Brepocitinib Shows Promise in Phase II Trial for PsA Oral tyrosine kinase 2/JAK-1 inhibitor improved both joint and skin manifestations Nov 07, 2021
Targeting IL-23 Succeeds in Psoriatic Arthritis Patients had active, longstanding disease and inadequate responses to other agents Nov 07, 2021
Can Abatacept Reverse Early Rheumatoid Arthritis? At-risk patients showed improvements in inflammation -- and also delays in disease onset Nov 06, 2021
No Love for PRP in Ankle Osteoarthritis Trial Dutch researchers throw cold water on popular therapy Oct 26, 2021
How Should Patients With Autoimmune Diseases Approach COVID Vaccination? Mixed messaging and a lack of tailored research leaves providers and patients in the dark Oct 22, 2021
First Interchangeable Humira Biosimilar Approved Cyltezo nabs coveted "interchangeable" status for RA, inflammatory bowel disease, and more Oct 18, 2021
In RA, Little Risk for Recurrent Cancer With Biologic Treatment Results important because most trials excluded patients with previous cancer, researchers note Sep 23, 2021
Statins Not Linked With Rheumatoid Arthritis, Large Study Finds Risks attenuated after adjustment for lipid levels Sep 22, 2021
IBD and Pediatric Arthritis: Exploring the Link Risk factors include enthesitis, family history, and etanercept use Sep 15, 2021
Lymphoma in RA: Disease Activity Matters Strongest risk factors were baseline disease activity scores and bone erosions Sep 08, 2021
FDA Slaps Restrictions on JAK Inhibitors Over Serious Safety Risks Use for inflammatory conditions limited to those who fail on TNF blockers Sep 01, 2021
What Factors Predict RA in First-Degree Relatives? Study may offer insight into preclinical phase to identify factors that predict progression Aug 12, 2021
New-Onset IBD and IL-17 Inhibitors: What Is the Risk? Underlying inflammatory disease severity should be taken into account Jul 21, 2021
CV Risk in PsA: Do Drugs Matter? Study weighs in on heart safety of TNF inhibitors versus other biologics Jul 19, 2021
Effective Treatments for Hand Osteoarthritis: The Search Goes On Hydroxychloroquine not effective as disease-modifying drug for erosive hand OA, trial confirmed Jul 08, 2021
Rinvoq Shows Promise in Spine Disease 1-year results in ankylosing spondylitis demonstrate efficacy for JAK inhibitor upadacitinib Jul 02, 2021
Target TNF or IL-12/23 in Psoriatic Arthritis? Both TNF inhibitors and ustekinumab were effective in real-world use Jun 30, 2021
New ACR Rheumatoid Arthritis Guideline: Emphasis on Methotrexate Many RA patients succeed with optimized use of the DMARD before adding another medication Jun 28, 2021
